Xeris Biopharma Holdings, Inc. 4

Beth Hecht, Chief Legal Officer of Xeris Biopharma Holdings, Inc., sold 16,666 shares of common stock at about $8.49 per share under a Rule 10b5-1 plan.

On 2026-09-01, Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc., sold 16,666 shares of the company’s common stock at a weighted average price of approximately $8.49 per share, for total proceeds of about $141,400. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025, and occurred in multiple transactions within a price range of $8.39 to $8.60 per share. Following this transaction, Hecht beneficially owned 1,127,796 shares of Xeris Biopharma common stock, which, using the reported sale price as a proxy, represent an equity stake with an indicative market value of roughly $9.6 million.

Filing Facts

CIK

1867096

Ticker

XERS

Form

4

Source Type

fda

Accession

0001652410-26-000018

Alert Tier

6